Exact Sciences Corporation (EXAS)
NASDAQ: EXAS · Real-Time Price · USD
53.30
+0.60 (1.14%)
Nov 21, 2024, 11:49 AM EST - Market open
Exact Sciences Revenue
Exact Sciences had revenue of $708.66M in the quarter ending September 30, 2024, with 12.78% growth. This brings the company's revenue in the last twelve months to $2.69B, up 11.91% year-over-year. In the year 2023, Exact Sciences had annual revenue of $2.50B with 19.93% growth.
Revenue (ttm)
$2.69B
Revenue Growth
+11.91%
P/S Ratio
3.58
Revenue / Employee
$407,928
Employees
6,600
Market Cap
9.86B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.50B | 415.49M | 19.93% |
Dec 31, 2022 | 2.08B | 317.19M | 17.95% |
Dec 31, 2021 | 1.77B | 275.70M | 18.49% |
Dec 31, 2020 | 1.49B | 615.10M | 70.19% |
Dec 31, 2019 | 876.29M | 421.83M | 92.82% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Henry Schein | 12.50B |
Encompass Health | 5.22B |
Catalent | 4.42B |
Charles River Laboratories International | 4.06B |
Exelixis | 2.08B |
Medpace Holdings | 2.07B |
Qiagen | 1.97B |
Sarepta Therapeutics | 1.64B |
EXAS News
- 1 day ago - Exact Sciences Corporation (EXAS) Jefferies London Healthcare Conference (Transcript) - Seeking Alpha
- 3 days ago - Exact Sciences Partners with Actor and TV Personality Carlos Ponce to Increase Awareness of Colon Cancer Screening Among Hispanic Community - Business Wire
- 7 days ago - Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy - Business Wire
- 11 days ago - Exact Sciences: Cancer Detection Stalwart's Bad Quarter Resets Its Overgrown Market Cap. - Seeking Alpha
- 14 days ago - Cologuard Maker Exact Sciences Slashes Outlook as Losses Mount - Investopedia
- 15 days ago - Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point - Benzinga
- 15 days ago - Exact Sciences Posts Downbeat Results, Joins Super Micro Computer, Honda Motor And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
- 15 days ago - Exact Sciences Corporation (EXAS) Q3 2024 Earnings Call Transcript - Seeking Alpha